source
- Novartis to buy Myricx Bio for up to $1.5 billion, adding two novel ADCs to its oncology portfolioNovartis announced it will acquire Myricx Bio, a UK‑based biotech that develops antibody drug conjugates (ADCs), in a move to broaden its oncology pipeline. The transaction is valued at up to $1.5…
- Cancer and immune-focused biotech firms capture over $3.9 billion of H1 2026 venture capitalBioPharma Dive data show that cancer and immune disease biotech companies accounted for more than 40% of the biotech firms receiving venture funding in the first half of 2026. Of the roughly $9 bi…